Alnylam Pharmaceuticals | ALNY - Pre Tax Profit

Stock Price
302.15
Daily Change
1.04 0.35%
Monthly
-5.44%
Yearly
9.26%
Q2 Forecast
289.95

Alnylam Pharmaceuticals reported $221.65M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Moderna USD -799M 612M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 5.17B 637M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 6.23B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.33B 32.2M Dec/2025
Xencor USD -4.27M 1.76M Dec/2025